These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36878391)

  • 1. Development of Triple-Negative Breast Cancer-Targeted Liposomes with MUC16 Binding Peptide Ligand in Triple-Negative Breast Cancer Cells.
    Hagimori M; Kato N; Orimoto A; Suga T; Kawakami S
    J Pharm Sci; 2023 Jun; 112(6):1740-1745. PubMed ID: 36878391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer.
    Suga T; Fuchigami Y; Hagimori M; Kawakami S
    Int J Pharm; 2017 Apr; 521(1-2):361-364. PubMed ID: 28237886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR.
    Chaudhary S; Appadurai MI; Maurya SK; Nallasamy P; Marimuthu S; Shah A; Atri P; Ramakanth CV; Lele SM; Seshacharyulu P; Ponnusamy MP; Nasser MW; Ganti AK; Batra SK; Lakshmanan I
    Breast Cancer Res; 2023 Mar; 25(1):25. PubMed ID: 36918912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of High-Functionality and -Quality Lipids with RGD Peptide Ligands: Application for PEGylated Liposomes and Analysis of Intratumoral Distribution in a Murine Colon Cancer Model.
    Suga T; Kato N; Hagimori M; Fuchigami Y; Kuroda N; Kodama Y; Sasaki H; Kawakami S
    Mol Pharm; 2018 Oct; 15(10):4481-4490. PubMed ID: 30179010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of High Functionality and Quality Cell-penetrating Peptide Conjugated Lipid for Octaarginine Modified PEGylated Liposomes In U251 and U87 Glioma Cells.
    El-Gamal FR; Akl MA; Mowafy HA; Mukai H; Kawakami S; Afouna MI
    J Pharm Sci; 2022 Jun; 111(6):1719-1727. PubMed ID: 34863974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-targeting liposomes with active recognition of GLUT
    Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
    Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
    Mirzavi F; Barati M; Vakili-Ghartavol R; Roshan MK; Mashreghi M; Soukhtanloo M; Jaafari MR
    Int J Pharm; 2022 Feb; 613():121396. PubMed ID: 34942328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
    Stras S; Howe A; Prasad A; Salerno D; Bhatavdekar O; Sofou S
    Mol Pharm; 2020 Jan; 17(1):118-131. PubMed ID: 31825626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 12. Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells.
    Hossein-Nejad-Ariani H; Althagafi E; Kaur K
    Sci Rep; 2019 Feb; 9(1):2723. PubMed ID: 30804365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer.
    Sneider A; Jadia R; Piel B; VanDyke D; Tsiros C; Rai P
    Oncomedicine; 2017; 2():1-13. PubMed ID: 28174679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC).
    Kanugo A; Gautam RK; Kamal MA
    Curr Pharm Biotechnol; 2022; 23(13):1581-1595. PubMed ID: 34967294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
    Guo P; Yang J; Huang J; Auguste DT; Moses MA
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide density targets and impedes triple negative breast cancer metastasis.
    Liu D; Guo P; McCarthy C; Wang B; Tao Y; Auguste D
    Nat Commun; 2018 Jul; 9(1):2612. PubMed ID: 29973594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
    Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
    Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.